Comparative Multi-Epitope-Ligand-Cartography reveals essential immunological alterations in Barrett's metaplasia and esophageal adenocarcinoma

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Berndt, Uta ^a   Philipsen, Lars ^b,d   Bartsch, Sebastian ^b   Hu, Yuqin ^a   Röcken, Christoph ^c   Bertram, Wiedenmann ^a   Hämmerle, Marcus ^b   Rösch, Thomas ^e   Sturm, Andreas ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b MelTec GmbH and Co KG   (Germany)

^c UNIVERSITY OF KIEL   (Germany)

^d OTTO VON GUERICKE UNIVERSITY   (Germany)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BCL 2; PROTEIN P53; EPITOPE; LIGAND;

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ESOPHAGEAL ADENOCARCINOMA; FEMALE; FUNCTIONAL PROTEOMICS; HELPER CELL; HUMAN; HUMAN TISSUE; IMAGING AND DISPLAY; IMMUNOPATHOGENESIS; LYMPHOCYTE COUNT; LYMPHOCYTE DIFFERENTIATION; MALE; MEMORY T LYMPHOCYTE; MUCOSAL IMMUNITY; MULTI EPITOPE LIGAND CARTOGRAPHY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; ADENOCARCINOMA; CASE CONTROL STUDY; COMPARATIVE STUDY; ESOPHAGUS TUMOR; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; PHENOTYPE; PROTEOMICS; T LYMPHOCYTE;

ADENOCARCINOMA; BARRETT ESOPHAGUS; CASE-CONTROL STUDIES; EPITOPES; ESOPHAGEAL NEOPLASMS; HUMANS; IMMUNITY, MUCOSAL; IMMUNOLOGIC MEMORY; LIGANDS; PHENOTYPE; PROTEOMICS; T-LYMPHOCYTES;

EID: 77955139571     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-177     Document Type: Article

References (46)

1. Wang KK, Sampliner RE. Updated Guidelines 2008 for the Diagnosis, Surveillance and Therapy of Barrett's Esophagus. Am J Gastroenterol 2008, 103:788-797. 10.1111/j.1572-0241.2008.01835.x, 18341497.
2. Sharma P, McQuaid K, Dent J, Fennerty MB, Sampliner R, Spechler S, Cameron A, Corley D, Falk G, Goldblum J, Hunter J, Jankowski J, Lundell L, Reid B, Shaheen NJ, Sonnenberg A, Wang K, Weinstein W. A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop. Gastroenterology 2004, 127:310-330. 10.1053/j.gastro.2004.04.010, 15236196.
3. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999, 340:825-831. 10.1056/NEJM199903183401101, 10080844.
4. Fitzgerald RC. Molecular basis of Barrett's oesophagus and oesophageal adenocarcinoma. Gut 2006, 55:1810-1820. 10.1136/gut.2005.089144, 1856460, 17124160.
5. Hornick JL, Odze RD. Neoplastic precursor lesions in Barrett's esophagus. Gastroenterol Clin North Am 2007, 36:775-96. 10.1016/j.gtc.2007.08.004, 17996790.
6. Dent J, El Serag HB, Wallander MA, Johansson S. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2005, 54:710-717. 10.1136/gut.2004.051821, 1774487, 15831922.
7. Sharma P. Review article: prevalence of Barrett's oesophagus and metaplasia at the gastro-oesophageal junction. Aliment Pharmacol Ther 2004, 20(Suppl 5):48-54. 10.1111/j.1365-2036.2004.02138.x, 15456464.
8. Ronkainen J, Aro P, Storskrubb T, Johansson SE, Lind T, Bolling-Sternevald E, Vieth M, Stolte M, Talley NJ, Agreus L. Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology 2005, 129:1825-1831. 10.1053/j.gastro.2005.08.053, 16344051.
9. Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS. Is there publication bias in the reporting of cancer risk in Barrett's esophagus?. Gastroenterology 2000, 119:333-338. 10.1053/gast.2000.9302, 10930368.
10. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002, 420:860-867. 10.1038/nature01322, 2803035, 12490959.
11. Berndt U, Philipsen L, Bartsch S, Wiedenmann B, Baumgart DC, Hammerle M, Sturm A. Systematic high-content proteomic analysis reveals substantial immunologic changes in colorectal cancer. Cancer Res 2008, 68:880-888. 10.1158/0008-5472.CAN-07-2923, 18245490.
12. Bonnekoh B, Pommer AJ, Bockelmann R, Hofmeister H, Philipsen L, Gollnick H. Topo-Proteomic in situ Analysis of Psoriatic Plaque under Efalizumab Treatment. Skin Pharmacol Physiol 2007, 20:237-252. 10.1159/000104422, 17587888.
13. Bode M, Irmler M, Friedenberger M, May C, Jung K, Stephan C, Meyer HE, Lach C, Hillert R, Krusche A, Beckers J, Marcus K, Schubert W. Interlocking transcriptomics, proteomics and toponomics technologies for brain tissue analysis in murine hippocampus. Proteomics 2008, 8:1170-1178. 10.1002/pmic.200700742, 18283665.
14. Berndt U, Bartsch S, Philipsen L, Danese S, Wiedenmann B, Dignass AU, Hammerle M, Sturm A. Proteomic analysis of the inflamed intestinal mucosa reveals distinctive immune response profiles in Crohn's disease and ulcerative colitis. J Immunol 2007, 179:295-304.
15. Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2002, 2:277-288. 10.1038/nrc776, 12001989.
16. Karin M. NF-kappaB and cancer: mechanisms and targets. Mol Carcinog 2006, 45:355-361. 10.1002/mc.20217, 16673382.
17. Bode AM, Dong Z. Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer 2004, 4:793-805. 10.1038/nrc1455, 15510160.
18. van Soest EM, Dieleman JP, Siersema PD, Sturkenboom MC, Kuipers EJ. Increasing incidence of Barrett's oesophagus in the general population. Gut 2005, 54:1062-1066. 10.1136/gut.2004.063685, 1774890, 15857935.
19. Irani S, Parkman HP, Thomas R, Krevsky B, Fisher RS, Axelrod P. Increased Barrett's esophagus for the decade between 1991 and 2000 at a single university medical center. Dig Dis Sci 2005, 50:2141-2146. 10.1007/s10620-005-3021-y, 16240229.
20. Vizcaino AP, Moreno V, Lambert R, Parkin DM. Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973-1995. Int J Cancer 2002, 99:860-868. 10.1002/ijc.10427, 12115489.
21. Atherfold PA, Jankowski JA. Molecular biology of Barrett's cancer. Best Pract Res Clin Gastroenterol 2006, 20:813-827. 10.1016/j.bpg.2006.04.003, 16997163.
22. Tozzi A, Staiano A, Paparo F, Miele E, Maglio M, Di Meo M, Simeone D, Troncone R. Characterization of the inflammatory infiltrate in peptic oesophagitis. Dig Liver Dis 2001, 33:452-458. 10.1016/S1590-8658(01)80021-9, 11572570.
23. Lucendo AJ, Navarro M, Comas C, Pascual JM, Burgos E, Santamaria L, Larrauri J. Immunophenotypic characterization and quantification of the epithelial inflammatory infiltrate in eosinophilic esophagitis through stereology: an analysis of the cellular mechanisms of the disease and the immunologic capacity of the esophagus. Am J Surg Pathol 2007, 31:598-606. 10.1097/01.pas.0000213392.49698.8c, 17414108.
24. O'Riordan JM, Abdel-Latif MM, Ravi N, McNamara D, Byrne PJ, McDonald GS, Keeling PW, Kelleher D, Reynolds JV. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Gastroenterol 2005, 100:1257-1264. 10.1111/j.1572-0241.2005.41338.x, 15929754.
25. Fitzgerald RC, Onwuegbusi BA, Bajaj-Elliott M, Saeed IT, Burnham WR, Farthing MJ. Diversity in the oesophageal phenotypic response to gastro-oesophageal reflux: immunological determinants. Gut 2002, 50:451-459. 10.1136/gut.50.4.451, 1773186, 11889061.
26. Fitzgerald RC, Abdalla S, Onwuegbusi BA, Sirieix P, Saeed IT, Burnham WR, Farthing MJ. Inflammatory gradient in Barrett's oesophagus: implications for disease complications. Gut 2002, 51:316-322. 10.1136/gut.51.3.316, 1773354, 12171950.
27. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006, 6:24-37. 10.1038/nrc1782, 16397525.
28. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 2006, 6:715-727. 10.1038/nri1936, 16977338.
29. Aggarwal BB. Nuclear factor-kappaB: the enemy within. Cancer Cell 2004, 6:203-208. 10.1016/j.ccr.2004.09.003, 15380510.
30. Boehme SA, Lenardo MJ. Propriocidal apoptosis of mature T lymphocytes occurs at S phase of the cell cycle. Eur J Immunol 1993, 23:1552-1560. 10.1002/eji.1830230724, 8325332.
31. Ju ST, Panka DJ, Cui H, Ettinger R, el Khatib M, Sherr DH, Stanger BZ, Marshak-Rothstein A. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 1995, 373:444-448. 10.1038/373444a0, 7530337.
32. Haynes BF, Denning SM, Singer KH, Kurtzberg J. Ontogeny of T-cell precursors: a model for the initial stages of human T-cell development. Immunol Today 1989, 10:87-91. 10.1016/0167-5699(89)90232-6, 2472811.
33. Stillwell R, Bierer BE. T cell signal transduction and the role of CD7 in costimulation. Immunol Res 2001, 24:31-52. 10.1385/IR:24:1:31, 11485208.
34. Karube K, Aoki R, Nomura Y, Yamamoto K, Shimizu K, Yoshida S, Komatani H, Sugita Y, Ohshima K. Usefulness of flow cytometry for differential diagnosis of precursor and peripheral T-cell and NK-cell lymphomas: analysis of 490 cases. Pathol Int 2008, 58:89-97.
35. Hao QL, George AA, Zhu J, Barsky L, Zielinska E, Wang X, Price M, Ge S, Crooks GM. Human intrathymic lineage commitment is marked by differential CD7 expression: identification of CD7- lympho-myeloid thymic progenitors. Blood 2008, 111:1318-1326. 10.1182/blood-2007-08-106294, 2214748, 17959857.
36. Moretta A, Marcenaro E, Parolini S, Ferlazzo G, Moretta L. NK cells at the interface between innate and adaptive immunity. Cell Death Differ 2008, 15:226-233. 10.1038/sj.cdd.4402170, 17541426.
37. Sturm A, Mohr S, Fiocchi C. Critical role of caspases in the regulation of apoptosis and proliferation of mucosal T cells. Gastroenterology 2002, 122:1334-1345. 10.1053/gast.2002.32996, 11984520.
38. Krammer PH, Arnold R, Lavrik IN. Life and death in peripheral T cells. Nat Rev Immunol 2007, 7:532-542. 10.1038/nri2115, 17589543.
39. Merkenschlager M, Beverley PC. Memory T cells. Nature 1989, 341:392. 10.1038/341392b0, 2797165.
40. Schubert W. Topological proteomics, toponomics, MELK-technology. Adv Biochem Eng Biotechnol 2003, 83:189-209.
41. Schubert W, Bonnekoh B, Pommer AJ, Philipsen L, Bockelmann R, Malykh Y, Gollnick H, Friedenberger M, Bode M, Dress AW. Analyzing proteome topology and function by automated multidimensional fluorescence microscopy. Nat Biotechnol 2006, 24:1270-1278. 10.1038/nbt1250, 17013374.
42. Pierre S, Maeurer C, Coste O, Becker W, Schmidtko A, Holland S, Wittpoth C, Geisslinger G, Scholich K. Toponomics Analysis of Functional Interactions of the Ubiquitin Ligase PAM (Protein Associated with Myc) during Spinal Nociceptive Processing. Mol Cell Proteomics 2008, 7:2475-2485. 10.1074/mcp.M800201-MCP200, 18753128.
43. Vellemann PF, Hoaglin DC. Applikacations, Basics, and Computing of Exlporatory Data Analysis. 1981, Duxbury Press.
44. McGill R. Variations of Boxplots. The American Statistician 1978, 32:12-16.
45. Nelson LS. Evaluating overlapping confidence intervals. Journal of quality technology 2006, 21:140-141.
46. Schubert W. Cytomics in characterizing toponomes: towards the biological code of the cell. Cytometry A 2006, 69:209-211.